文献速递瓣膜病与结构性心脏病血脂与心血管预防

机械心脏瓣膜患者使用非维生素K拮抗剂口服抗凝药:大门是否仍敞开?

Non-Vitamin K Antagonist Oral Anticoagulants for Mechanical Heart Valves: Is the Door Still Open?
PubMed 文献 · Circulation · 2018-01-01

本文针对机械心脏瓣膜患者绝对禁用非维生素K拮抗剂口服抗凝药(NOACs)的现行观点提出再评估。作者认为,仅基于一项比较达比加群与华法林的II期研究(RE-ALIGN)的阴性结果就否定NOACs证据不足,主张重新审视临床前研究与RE-ALIGN试验的若干方面,并识别最可能从某些NOACs(尤其是Xa因子抑制剂)获益的患者特征,为基础与转化研究提供方向。

要点

  • 机械瓣膜需终身抗凝,现行指南基于RE-ALIGN试验将NOACs列为绝对禁忌。
  • 作者认为单项单药试验证据不足以否定NOACs在机械瓣膜中的治疗策略。
  • 应重新评估临床前与RE-ALIGN数据,聚焦Xa因子抑制剂和特定患者特征。

核心结论

  • 仅凭一项使用单一NOAC的II期试验不足以否定NOACs用于机械心脏瓣膜抗凝的策略。
  • 需重新评估临床前研究和RE-ALIGN试验,识别最可能从Xa因子抑制剂等NOACs获益的患者特征。

研究设计与样本

  • 本文为针对机械心脏瓣膜患者使用NOACs的再评估性论述,非系统综述或原始研究。
  • 主要引用一项比较达比加群与华法林的II期研究(RE-ALIGN)及临床前研究进行批判性分析。

主要发现

  • RE-ALIGN试验因所测试达比加群剂量下卒中与出血事件过多而提前终止。
  • 作者指出,NOACs在房颤和静脉血栓栓塞症中显示比华法林更好的安全性及至少相似的有效性。
  • 作者认为机械瓣膜目前对NOACs的绝对禁忌是基于单一试验的阴性结果。

关键数值与推荐

  • 西方一般人群二尖瓣或主动脉瓣膜性心脏病估计患病率约2.5%,随人口老龄化预计上升。
  • 机械心脏瓣膜因血栓源性较高需终身抗凝以预防瓣膜血栓。
  • RE-ALIGN试验因达比加群组卒中和出血过多而提前终止。

临床怎么用

  • 当前机械心脏瓣膜患者仍应遵循NOACs绝对禁忌的现行推荐。
  • 临床决策需等待针对特定NOACs和患者特征的前瞻性研究证据。
  • 关注Xa因子抑制剂在机械瓣膜患者中的潜在研究进展。

局限性

  • 本文为观点性论述,未提供新的原始研究数据。
  • 作者观点基于对现有文献的再评估,需后续研究验证。
  • RE-ALIGN试验仅评估达比加群,结果不能外推至所有NOACs。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The estimated prevalence of mitral or aortic valvular heart disease is ≈2.5% in the general population of Western countries, and is expected to rise with population aging. A substantial proportion of patients with valvular heart disease undergoes surgical valve replacement. Mechanical heart valves are much more durable than bioprostheses, and are thus preferentially implanted in patients with a longer life expectancy, but have the major drawback of requiring lifelong anticoagulation to prevent valve thrombosis because of their higher thrombogenicity. The non-vitamin K antagonist oral anticoagulants (NOACs) are replacing vitamin K antagonists in many settings, including bioprostheses, because of their favorable safety and efficacy profiles. However, mechanical heart valves currently pose an absolute contraindication to NOACs based on the results of a single phase II study comparing dabigatran and warfarin (RE-ALIGN [Randomized, Phase II Study to Evaluate the Safety and Pharmacokinetics of Oral Dabigatran Etexilate in Patients after Heart Valve Replacement]). That trial was stopped prematurely because of an excess of both stroke and bleeding with the dabigatran doses tested. Because of such negative findings, research in this area has been halted. We believe that several aspects of both the preclinical studies and the RE-ALIGN trial should be critically reevaluated. In our opinion, 1 single trial with a single NOAC does not represent sufficient evidence for dismissing a therapeutic strategy, anticoagulation with NOACs, that has shown better safety and at least similar efficacy as warfarin in the setting of atrial fibrillation and venous thromboembolism,. Herein, we reevaluate this topic to identify the patient profile that has the greatest likelihood of benefit from some of the NOACs, with a focus on factor Xa inhibitors, thus providing some perspectives for basic and translational research.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Aimo A, Giugliano RP, De Caterina R, et al. Non-Vitamin K Antagonist Oral Anticoagulants for Mechanical Heart Valves: Is the Door Still Open? Circulation. 2018. PMID: 30354416. doi:10.1161/CIRCULATIONAHA.118.035612

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。